Pharmaceutical - Financial, Patents

Filter

Current filters:

FinancialPatents

Popular Filters

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Low level of “potentially problematic” patent settlements in EU pharma sector

Low level of “potentially problematic” patent settlements in EU pharma sector

09-12-2013

The European Commission's report on patent settlement agreements, also referred to as “pay-for-delay”…

EuropeFinancialGenericsPatentsPharmaceutical

Teva denies claims its MS drug Copaxone profits set to slump

Teva denies claims its MS drug Copaxone profits set to slump

25-11-2013

Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, this morning strongly…

CopaxoneEuropeFinancialMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

US pharma patent settlements netted $25.5 billion in savings for health system; report

10-07-2013

Generic pharmaceuticals launched prior to patent expiration due to a patent settlement - also called…

FinancialGenericsNorth AmericaPatentsPharmaceutical

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Tightening health budgets on both sides of the Atlantic leading to crackdowns on patent settlements, says EIU analyst

05-06-2013

Later this month, following an inquiry launched in 2009, the European Commission is expected to impose…

EuropeFinancialGenericsNorth AmericaPatentsPharmaceuticalPoliticsRegulation

Europe falling behind USA and China as attractive for life sciences sector

22-04-2013

Intellectual property specialists Marks & Clerk's latest Life Sciences Report unveils the changing landscape…

BiotechnologyFinancialGlobalPatentsPharmaceuticalRegulationResearch

Vision for "better health through research" in Australia set out in new report

05-04-2013

Australian Minister for Health Tanya Plibersek on April 5 released the report of the McKeon Review -…

Asia-PacificBiotechnologyFinancialPatentsPharmaceuticalResearch

Daiichi Sankyo sets out five-year plan to overcome Olmetec patent expiry

25-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has announced a new five-year Business Plan, which will…

Daiichi SankyoFinancialolmesartanOlmetecPatentsPharmaceuticalRanbaxy Laboratories

New approach to drug discovery urged by US academician

17-02-2013

Garret FitzGerald, chairman of the Department of Pharmacology and Director of the Institute for Translational…

BiotechnologyFinancialNorth AmericaPatentsPharmaceuticalResearch

Drugmakers to continue facing growing generic competition in 2013

17-02-2013

Last year saw the expiration of patents for several blockbuster drugs, leading to increasing generic…

AmarinFinancialForest LaboratoriesGenericsPatentsPharmaceutical

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

12-12-2012

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Overview of Novartis' patent losses from GlobalData

11-10-2012

Swiss drug major Novartis (NOVN: VX) is the latest victim of patent protection loss, note analysts at…

DiovanFemaraFinancialGleevecNovartisPatentsPharmaceuticalReclastZometa

European Unitary Patent and Patent Box dominate the London patent summit

11-10-2012

With a key meeting on the 40-year old saga of the European Single Unitary Patent scheduled for December…

FinancialPatentsPharmaceutical

Pharma vs the world: Big Pharma caught between investors and public

23-09-2012

Big Pharma today encounters a variety of pressures from generics manufacturers, governments, patient…

FinancialGenericsGlobalMarkets & MarketingPatentsPharmaceuticalPoliticsSanofi

Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute

30-04-2012

US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion,…

FinancialLegalMerck & CoMylan LaboratoriesNorth AmericaPatentsPharmaceuticalVytorinZetia

Sanofi fourth-quarter in line with forecasts; collects damages

08-02-2012

French drug major Sanofi (Euronext: SAN) this morning reported 8.8% growth in fourth-quarter 2011 sales…

ApotexBristol-Myers SquibbFinancialGenericsLegalPatentsPharmaceuticalPlavix

Pharma industry could use a shot in the arm, says Fitch; FT views bribery settlements

23-01-2012

2012 will be a critical year for the pharmaceutical industry, as drugmakers struggle with record patent…

FinancialLegalMarkets & MarketingPatentsPharmaceuticalResearch

Novartis cuts jobs, takes $1.22 billion charges

13-01-2012

In anticipation of the blockbuster antihypertensive Diovan’s (valsartan) patent expiration and an…

DiovanFinancialManagementNovartisPatentsPharmaceuticalRasilezTekturna

Back to top